Epigral has reported its Q2 FY25 financial results, showing a significant year-over-year (YoY) increase in both revenue and net profit.
For the quarter ended September 30, 2024, Epigral recorded a revenue from operations of ₹626.06 crore, a substantial rise from ₹478.15 crore in the corresponding quarter last year, marking a growth of approximately 31%. On a quarter-over-quarter (QoQ) basis, revenue showed a slight decrease from ₹651.20 crore in the previous quarter (June 2024).
Net profit for Q2 FY25 stood at ₹81.30 crore, a sharp increase from ₹37.99 crore in Q2 FY24, reflecting a YoY growth of over 114%. Compared to the previous quarter, where the net profit was ₹85.87 crore, there was a modest QoQ decline.
The company’s performance underscores a strong annual growth trajectory, despite a slight quarter-over-quarter dip.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
